Blood Cancer Journal

Papers
(The H4-Index of Blood Cancer Journal is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M209
Disparities in time to treatment with oral antimyeloma medications187
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity169
Correction: Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells126
Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes115
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine100
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study87
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes81
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor79
Genomic landscape of hyperleukocytic acute myeloid leukemia79
A multiparametric niche-like drug screening platform in acute myeloid leukemia77
Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia75
Dynamics of microcyst-like epithelial changes associated with Belantamab mafodotin therapy in a patient with multiple myeloma—a case report75
Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease74
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management70
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma64
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma63
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency63
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort62
Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study61
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma53
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib53
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT52
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma49
In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study49
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid48
Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma48
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients44
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study43
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression43
Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia43
Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review42
Assessing the performance of the Iceland screens, treats, or prevents multiple myeloma (iStopMM) model in a multicultural Bronx cohort: implications for monoclonal gammopathy of undetermined significa41
The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy41
CALRins5-mediated clonal hematopoiesis causes severe hemolytic anemia in a female PGK1Ser320Asn carrier40
Genome profiling with targeted adaptive sampling long-read sequencing for pediatric leukemia40
RSK1 dependency in FLT3-ITD acute myeloid leukemia37
Should I stay or should I go (to transplant)? Managing insufficient responses to induction in multiple myeloma37
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma37
0.11184597015381